Freedom of Information Requests to Scandinavian and International Health Authorities

This document compiles the full record of Freedom of Information (FOI) requests submitted by the author to health authorities in six countries: Denmark, Sweden, Norway, the United Kingdom, Australia, and the United States. The central question posed to each authority was whether they possess documentation of measurable biological causes for psychiatric diagnoses classified under ICD-10/ICD-11/DSM-5, and whether pharmacological treatments used for these diagnoses have been documented to correct or normalise a demonstrated biological abnormality. The requests were submitted between October 2025 and February 2026. Completed responses have been received from Denmark (Ministry of the Interior and Health, and the Danish Health Authority/Sundhedsstyrelsen), Sweden (Socialstyrelsen and Läkemedelsverket), and Norway (Helsedirektoratet). The request to the United Kingdom (MHRA) is pending response, the Australian request (TGA) was redirected due to jurisdictional limitations, and the United States (FDA) declined to process the request. The consistent finding across all completed responses is that none of the authorities contacted possess documentation establishing measurable biological causes for psychiatric diagnoses, clinical threshold values for biological parameters used in psychiatric diagnosis, or evidence that psychiatric medications correct an identified biological abnormality. Every authority that provided a substantive response answered “No” to these core questions. The Danish Health Authority explicitly confirmed “No” to all six targeted yes/no questions regarding biological evidence. The Norwegian Directorate of Health stated that their guidelines do not establish biological diagnostic markers for psychiatric disorders, nor do they contain biomarker-based criteria for initiating, adjusting, or discontinuing psychiatric medication. The Swedish Medical Products Agency (Läkemedelsverket) confirmed that it does not possess documentation of biological markers for psychiatric diagnosis, that no biological parameters are used to determine when psychiatric medication should be initiated, adjusted, or discontinued, and that there is no legal requirement for approval documentation to show that a medication corrects a biological abnormality. The Swedish National Board of Health and Welfare (Socialstyrelsen) answered “No” to all questions regarding biological evidence and referred medication-specific questions to Läkemedelsverket. These responses, obtained through formal legal channels and documented in official government correspondence, represent a significant body of evidence regarding the current state of biological evidence underlying psychiatric diagnosis and treatment across multiple national health systems.